



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner For Patents, Washington, D.C. 20231 on June 14, 2002

David V. Upite 47,147
Name of Attorney Registration No.
Signature of Attorney *David V. Upite*

Case 7564

8
281 1128103
87W
RECEIVED
JAN 22 2003
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of :

SONG LIU

MIN LI

Serial No.: 09/979,561 ✓

Group Art Unit:

Confirmation No.: 5953

Filed: 5/16/2000

: Examiner:

For: PROCESS FOR MAKING FUSED-RING IMIDAZO-CONTAINING
COMPOUNDS ✓

RECEIVED
JUN 24 2002
TECHNOLOGY CENTER 2800

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner For Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made below in a Form PTO-1449 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO-1449 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

1. ☐ 37 C.F.R. §1.97 (b)(1) - U.S. Direct (within 3-months of filing a regular application or converted provisional)

This information disclosure statement, submitted under 37 C.F.R. §1.97 (b)(1), is being filed within three months of the filing date of a national application. Therefore, no fee is believed to be due.

2. ☐ 37 C.F.R. §1.97 (b)(2) - Via PCT (within 3 mo. of Nat'l Stage Entry)

This information disclosure statement, submitted under 37 C.F.R. §1.97 (b)(2), is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application. Therefore, no fee is believed to be due.

3. ☒ 37 C.F.R. §1.97 (b)(3) - (>3 mo. after filing direct or nat'l stage entry, but before 1st O.A.)

This information disclosure statement is being submitted under 37 C.F.R. §1.97 (b)(3). Applicants have not received an Office Action on the merits in the present application. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant to 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter is enclosed to facilitate charging of the fee, if necessary.

THE FOLLOWING IS ADDITIONAL INFORMATION PERTAINING TO (2) OR (3) MARKED WITH AN (X) ABOVE.

(a) ☐ The Notification of Acceptance of this Application Under 35 U.S.C. §371 indicates that both a copy of the International Search Report and copies of the references cited therein are present in the national stage file. In accordance with MPEP §1893.03(g), it is respectfully requested that the Examiner note the consideration of these references in the first Office Action via the PTO-892 form.

(b) ☐ The Notification of Acceptance of this Application Under 35 U.S.C. §371 indicates that a copy of the International Search Report is present in the national stage file. Copies of the references cited in that report are enclosed. It is respectfully requested that the Examiner note the consideration of these references in the first Office Action via the PTO-892 form.

(c) ☐ The Notification of Acceptance of this Application Under 35 U.S.C. §371 does not indicate that a copy of the International Search Report and copies of the references cited are present in the national stage file. Copies of the International Search Report and references are attached.

4. ☐ 37 C.F.R. §1.97(c) with fee payment - (use after 1st Office Action & before Final Office Action or Notice of Allowance)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). Applicant(s) have not received a final action under 37 C.F.R. §1.113 or a notice of allowance under 37 C.F.R. §1.311 as of the date of this submission. Applicant(s) elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter is enclosed to facilitate the charging of the fee.

ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:

☐ (1) Copies of the cited references were previously cited by or submitted to the USPTO in prior application Case No. ____, U.S. Patent Application Serial No. __, filed __. Applicants claim priority to said application under 35 U.S.C. §120. Accordingly, copies of those documents are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d).

OR

☒ (2) Copies of the cited documents are enclosed.

OR

☐ (3) Copies of all said documents, except document No.'s _____, were submitted and considered in parent application U.S. Patent Application Serial No. _____, filed _____. Applicant(s) claim priority to said application under 35 U.S.C. §120. Accordingly, copies of document No.'s _____ are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d). Copies of document No.'s _____ are enclosed. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case.


☐ (4) Pursuant to 37 C.F.R. §1.98(c), a concise explanation of the relevance of each cited reference that is not in the English language is on the attached page, except where a full English language translation is provided.

☒ (5) Applicants also respectfully request the Examiner to consider and make of record the copending applications listed on the attached page.

☐ Additional information is attached.

Respectfully submitted,

SONG LIU, ET AL

By 
David V. Urite
Attorney for Applicant
Registration No. 47,147
(513) 622-1825

Customer No. 27752

Date: _____, 2002
Mason, OH 45040

COPENDING APPLICATIONS

<u>Atty Docket No.</u>	<u>Serial Number</u>	<u>Inventors(s)</u>	<u>Filing Date</u>
7563	PCT/US00/13413 WO 00/69860	SONG LIU, ET AL	5/16/2000
7295	09/399,018 WO 00/21964	SONG LIU, ET AL	09/21/1999

RECEIVED
JAN 22 2003
TECH CENTER 1600/2900



TECHNOLOGY CENTER 2800

RECEIVED
JUN 24 2002RECEIVED
JAN 24 2003
TECH CENTER 1600/2900

LIST OF DOCUMENTS CITED BY APPLICANTS (Use several sheets if necessary)	ATTY. DOCKET NO. 7564	SERIAL NO. 09/979,544
APPLICANT Liu et al.		
FILING DATE 5/16/2000		GROUP

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	3,917,610	11/04/75	Takacs et al.	260	288	
	4,143,143	03/06/79	Seiler	424	258	
	6,159,985	12/12/00	Liu et al.	514	292	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION YES NO
	• DE 135,724	05/23/79	Germany	C07D	265/50	x
	• JP 49-048,663	09/13/72	Japan	16E362	30B1	x
	• JP 54-048,763	04/17/79	Japan	C07D	233/70	x
	• JP 54-112,864	09/04/79	Japan	C07D	233/80	x
	• JP 07,112,975	05/02/95	Japan	C07D	233/88	x
	• JP 08,291,173	11/05/96	Japan	C07D	471/04	x
	• WO 92/06080	04/16/92	PCT	C07D	233/88	
	• WO 92/09278	06/11/92	PCT	A61K	31/415	
	• WO 92/10179	06/25/92	PCT	A61K	31/41	
	• WO 92/10180	06/25/92	PCT	A61K	31/41	
	• GB 1438819A	07/09/76	UK	C07D	471/04	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	• BORCHARD et al., "The Positive Inotropic, Antiarrhythmic and Na ⁺ , K ⁺ -ATPase Inhibitory Effects of the Isoquinoline Derivative, BIIA", <u>Naunyn-Schmiedeberg's Arch. Pharmacol.</u> , 312 (1980) pp. 187-192. (Chemical Abstract attached).
	• HALA et al., "Electrical and Mechanical Activity of the Myocardium as Affected by CH-101, an Antiarrhythmic Agent with Preferential Supraventricular Action", <u>Adv. Pharmacol. Res Pract., Proc. Congr Hung Pharmacol. Soc.</u> , (1986), Vol 1, pp 163-7 (Chemical Abstract attached).
	• FOX et al., "Mechanism of Inhibition of Sodium- and Potassium-Dependent Adenosine Triphosphatase by the Isoquinoline Derivative BIIA: A Specific Interaction With Sodium Activation", <u>Biochemical Pharmacology</u> , 30 (1981) pp. 611-617.
	• ZOLYOMI et al., "Potential Drugs Labelled with ¹⁴ C. I. The Synthesis of 3-Benzylamino-5,6-dihydro-8,9-dimethoxy-imidazo[5,1-a]isoquinoline hydrochloride", <u>J. of Labelled Compounds and Radiopharmaceuticals</u> , XVIII (1980) pp. 813-822.
	• BORCHARD et al., "Characterization of Antiarrhythmic Drugs by Alternating Current Induced Arrhythmias in Isolated Heart Tissues", <u>Arch. Int. Pharmacodyn.</u> , 256 (1982) pp. 253-268.
	• FULOP et al., "A 3-Benzylamino-5,6-dihydro-8,9-dimethoxy-imidazo-(5,1-a)-izokinolin-hidroklorid es Intermedierjei Negyszoghullamu Polarografias Vizsgalata", <u>Magyar Kemiai Folyoirat</u> , 89 (1983) pp. 293-297.
	• KEENAN et al., Imidazole-5-acrylic Acids: Potent Nonpeptide Angiotensin II Receptor Antagonists Designed Using a Novel Peptide Pharmacophore Model "J. Med. Chem. 1992. Vol. 35, No. 21, 3858-3872.
	• MIYAURA et al., The Palladium-Catalyzed Cross-Coupling Reaction of Phenylboronic Acid with Haloarenes in the Presence of Bases, "Synthetic Communications 1981 11(7). 513-519.
	• O'CONNELL et al, Convenient Synthesis of Methyl 1-Methyl-2,4-dibromo-5 imidazolecarboxylate "Synthesis", October 1988, pp 767-771

EXAMINER DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Patent and Trademark Office - U.S. DEPARTMENT OF COMMERCE

LIST OF DOCUMENTS CITED BY APPLICANTS (Use several sheets if necessary)	ATTY. DOCKET NO. 7564	SERIAL NO. 09/979,561
	APPLICANT Liu et al.	
	FILING DATE 5/16/2000	GROUP 1612

	/	RAPOPORT et al, J. Organic Chemistry, 1992, Vol 57, Pg 1390
)	LIPSHUTZ et al, Metalations of Imidazoles (poly) Functionalization and conversions to Imidazolones, Tetrahedron Letters 1988, 29(28) 3411-3414.
	>	WHITTEN, et al, [2-(Trimethylsilyl) ethoxy] methyl (SEM) as a Novel and Effective Imidazole and fused Aromatic Imidazole Protecng Group, J of Organic Chemistry 1986, 51, 1891-1894.
	/	PRIIMENKO et al, Investigations in the Imidazole Series LXV. Synthesis of 2-Aminoimidazole Derivatives from 2-Haloimidazoles, pp. 1173-1176.
	/	NISHIMURA, et al Mechanism of Voges-Proskauer Reaction, Chemistry Letters, Chemical Society of Japan (1972, pp 649-652
	/	NISHIMURA et al, A Novel Synthesis of 2-(disubstituted amino)-5(4) phenylimidazoles, Dept of Chemistry, School of Hygienic Sciences, Feb 7, 1975, Vol 12, pp. 47-476.
	/	CHOSHI et al., Synthesis of Mutagenic Heterocyclic Amines PhIP and DMIP, J. Org. Chem, Vol. 58 No. 27, 1993, pp. 7952-7954.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

Patent and Trademark Office - U.S. DEPARTMENT OF COMMERCE



RECEIVED
JUN 24 2002
TECHNOLOGY CENTER 2800



RECEIVED

JAN 22 2003

TECH CENTER 1600/2900

Sheet 3 of 3

Serial No.: 09/979,561

PTO-1449 SUPPLEMENT FOR P&G CASE 7564
CO-PENDING APPLICATIONS

<u>Examiner Initial</u>	<u>Serial Number</u>	<u>Inventor(s)</u>	<u>Attorney Docket#</u>	<u>Filing Date</u>
	PCT/7200/13413 WO 00/69860	SONG LIU, ET AL	7563	05/16/2000
	09/399,018 WO 00/21964	SONG LIU, ET AL	7295	09/21/1999

RECEIVED
JUN 24 2002
TECHNOLOGY CENTER 2800